Treatment of BRL 28500 (clavulanic acid-ticarcillin) for infections in patients with hematological diseases

Keisuke Toyama, Shinichiro Okamoto, Hiroshi Uchida, Yasuhiko Ando

Research output: Contribution to journalArticle


BRL 28500, ticarcillin combined with clavulanic acid, was evaluated clinically for infections in 5 patients with hematological diseases. BRL 28500 was administrated by one-hour drip intravenous infusion at a daily dose of 12.8g for 4 to 10 days. Duration of BRL 28500 therapy was determined according to the patient's condition. Five cases consisted of 2 cases with possible septicemia, 2 cases with pneumonia and/or possible septicemia and one with cellulitis. The clinical response to BRL 28500 therapy of possible septicemia was good in one case, but all other cases did not respond to BRL 28500. No significant side effect was observed after the administration of BRL 28500.

Original languageEnglish
Pages (from-to)452-454
Number of pages3
Publication statusPublished - 1986 Jan 1


ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology

Cite this